Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529

References

• Ribi E, Parker R etal. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol. Immunother. 7, 43–58 (1979).
   Google Scholar
• Saha DC, Barua RS, Astiz MT et al. Monophosphoryl lipid A stimulated upregulation of reactive oxygen intermediates in human monocytes in vitro. .1. Leukoc. Biol. 70(3), 381–385 (2001).
   Google Scholar
• De Becker G, Moulin V, Pajak B et al The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12(6), 807–815 (2000).
   PubMed Web of Science ®Google Scholar
• Ismaili J, Rennesson J, Aksay E et al Monophosphoryl lipid A activates both human dendritic cells and T-cells.Immunol 168(2), 926–932 (2002).
   Web of Science ®Google Scholar
• Persing DH, Coler RN, Lacy MJ et al Taking Toll: lipid A mimetics as adjuvants and immunomodulators. 7i-ends Nlicrobiol. 10(10), S32—S37 (2002).
   Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol 6, 495–524 (1995).
   Google Scholar
• ••Excellent in-depth review of MPLadjuvant.
   Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Vaccine Design: the Subunit and Adjuvant Approach. Powell MF, Newman MJ (Eds). Plenum, NY, USA, 495–524 (1995).
   Google Scholar
• Baldridge JR, Buchmeier MJ. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Viral 66(7), 4252–4257 (1992).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Yorgensen Y, Ward JR et al Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18 (22), 2416–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Wijburg OL, van den Dobbelsteen GP, Vadolas J et al. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. I Immunol 28(2), 479–487 (1998).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injection. Allergy 56, 498–505 (2001).
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Bernstein H, Pelton S et al. Effect of monophosphoryl lipid A (MPL°) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM(197) conjugate vaccine in healthy toddlers. Vaccine 20(31–32), 3658–3667 (2002).
   Google Scholar
• Baldridge JR. A synthetic adjuvant, RC-529, moves into the clinic. 3rd Meeting on Novel Adjuvants Currently in/close to Human Clinical Tsang WHO/TDR - Fondation Merieux, (2002).
   Google Scholar
• DuPont J-C, Altclas J et al Efficacy and safety of AgB/RC529: a novel two dose adjuvant vaccine against hepatitis B. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002).
   Google Scholar
• Thoelen S, Van Damme P, Mathei C et al Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16(7), 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• Thoelen S, De Clercq N, Tornieporth NA. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 19(17-19), 2400–2403 (2001).
   PubMed Web of Science ®Google Scholar
• Desombere I, Van der WM, Van Damme P et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/A504, a hepatitis B vaccine with a novel adjuvant. Vaccine 20(19–20), 2597–2602 (2002).
   Google Scholar
• Jacques P, Moens G, Desombere I et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 (31-32), 3644–3649 (2002).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner G et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl. J. Med. 336(2), 86–91 (1997).
   Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J. Med. 347(21), 1652–1661 (2002).
   Web of Science ®Google Scholar
• Corey L, Langenberg AG, Cunningham AL et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4), 331–340 (1999).
   Google Scholar
• Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883–5893 (1988).
   Google Scholar
• Harel W, Goedegebuure PS et al. Melanoma-specific lysis by cloned CD4+ and CD8+ T-cells from actively immunized melanoma patients. Vaccine Res. 2(1), 41–53 (1993).
   Google Scholar
• Mitchell MS, Liggett PE, Green RL et al. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J. Clin. Oncol 12(2), 396–401 (1994).
   Google Scholar
• Mitchell MS, Jakowatz J, Harel W et al. Increased effectiveness of interferon a-2b following active specific immunotherapy for melanoma.J Clin. OncoL 12(2), 402–411 (1994).
   Google Scholar
• Sosman JA, Unger JM, Harel W et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. OncoL 20(8), 2067-2075 (2002).
   Google Scholar
• Johnson DA, Keegan DS, Sowell CG et al. 3- O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem. 42,4640-4649 (1999).
   Google Scholar
• Johnson DA, Sowell CG, Johnson CL et al Synthesis and biological evaluation of a new class of vaccine adjuvants: Aminoalkyl glucosaminide 4-phosphates (AGPs) Bioorg. fed. Chem. Lett. 9 (15), 2273–2278 (1999).
   Google Scholar
• •Details the synthesis and biological activity of a novel class of synthetic TLR4 agonists.
   Google Scholar
• Brandenburg K, Funari SS, Koch MH, Seydel U. Investigation into the acyl chain packing of endotoxins and phospholipids under near physiological conditions by WAXS and FTIR spectroscopy. J. Struct. Biol. 128 (2), 175–186 (1999).
   Google Scholar
• •Importance of lipid A acyl chain length and packing on biological activity.
   Google Scholar
• Brandenburg K, Schromm AB, Koch MH, Seydel U. Conformation and fluidity of endotoxins as determinants of biological activity. Frog: Clin. Biol. Res. 392,167-182 (1995).
   Google Scholar
• Seydel U, Labischinski H, Koch MH, Brandenburg K. Phase behavior, supramolecular structure and molecular conformation of lipopolysaccharide. Immunobiology187(3-5), 191–211 (1993).
   PubMed Web of Science ®Google Scholar
• Brandenburg K, Matsuura M, Heine H et al Biophysical characterization of triacyl monosaccharide lipid a partial structures in relation to bioactivity. Biophys. 83(1), 322–333 (2002).
   Google Scholar
• Fukase K, Oikawa M, Suda Y et al New synthesis and conformational analysis of lipid A: biological activity and supramolecular assembly. J. Endotoxin Res. 5(1/2), 46–51 (1999).
   Google Scholar
• Fukuoka S, Brandenburg K, Muller M, Lindner B, Koch MH, Seydel U. Physicochemical analysis of lipid A fractions of lipopolysaccharide from Erwinia carotovora in relation to bioactivity. Biochim. Biophys. Acta 1510(1–2), 185–197 (2001).
   Google Scholar
• Han J, Ulevitch RJ. Emerging targets for anti-inflammatory therapy. Nat. Cell Biol. 1(2), E39—E40 (1999).
   Web of Science ®Google Scholar
• Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589(1), 1–13 (2002).
   Google Scholar
• Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. ImmunoL 2(10), 947–950 (2001).
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev Immunol 1, 135–145 (2001).
   PubMed Web of Science ®Google Scholar
• Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406(6797), 782–787 (2000).
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the role of TLR in the induction of innate immunity.
   Google Scholar
• Poltorak A, He X, Smirnova I et al Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 282(5396), 2085-2088 (1998).
   Google Scholar
• ••First identification of a microbial product (LPS) as a TLR agonist.
   Google Scholar
• Poltorak A, Ricciardi-Castagnoli P et al. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Bun Natl Acad. Li. USA 97(5), 2163–2167 (2000).
   Google Scholar
• Baldridge JR, Cluff C et al. Non-specific resistance and immunostimulatory activity of aminoalkyl glycosaminide 4-phosphates (AGPs): activation of host immune systems by RC-524 and RC-529../. Enclotoxin Res. (2003) (In Press).
   Google Scholar